Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - Anixa Biosciences Inc | form10k.htm |
| EX-99.1 - EXHIBIT 99.3 - Anixa Biosciences Inc | exhibit99_3.htm |
| EX-99.2 - EXHIBIT 99.2 - Anixa Biosciences Inc | exhibit99_2.htm |
| EX-99.1 - EXHIBIT 99.1 - Anixa Biosciences Inc | exhibit99_1.htm |
| EX-32.2 - EXHIBIT 32.2 - Anixa Biosciences Inc | exhibit32_2.htm |
| EX-32.1 - EXHIBIT 32.1 - Anixa Biosciences Inc | exhibit32_1.htm |
| EX-31.2 - EXHIBIT 31.2 - Anixa Biosciences Inc | exhibit31_2.htm |
| EX-31.1 - EXHIBIT 31.1 - Anixa Biosciences Inc | exhibit31_1.htm |
| EX-21 - EXHIBIT 21 - Anixa Biosciences Inc | exhibit21.htm |
| EX-10.21 - EXHIBIT 10.21 - Anixa Biosciences Inc | exhibit10_21.htm |
| EX-10.20 - EXHIBIT 10.20 - Anixa Biosciences Inc | exhibit10_20.htm |
| EX-10.19 - EXHIBIT 10.19 - Anixa Biosciences Inc | exhibit10_19.htm |
| EX-4.2 - EXHIBIT 4.2 - Anixa Biosciences Inc | exhibit4_2.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Post-Effective Amendment No. 2 to the Registration Statement on Form S-1 on Form S-3 (No. 333-193869), Amendment No. 1 to the Registration Statement on Form S-3 (No. 333-206782) and the Registration Statement on Form S-8 (No. 333-202473) of ITUS Corporation (the “Company”) of our report dated December 7, 2016 relating to our audit of the Company’s consolidated financial statements as of October 31, 2016 and 2015, and for each of the years then ended, included in the Company’s Annual Report on Form 10-K for the year ended October 31, 2016.
Our report dated December 7, 2016, contains an explanatory paragraph that states that the Company has limited working capital and limited revenue-generating operations and a history of net losses and net operating cash flow deficits. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
HASKELL & WHITE LLP
Irvine, California
December 7, 2016